Carl Novina

Carl is an Associate Professor of Medicine at the Dana-Farber Cancer Institute & Harvard Medical School and an Associate Member of the Broad Institute of Harvard and MIT. His original research has resulted in the founding of Raqia Therapeutics, Sana Rx and Mana Therapeutics. He is the recipient of numerous awards and honors, including the W.M. Keck Distinguished Young Scholars Award, Department of Defense Idea Award, The NCI Director’s Provocative Questions Award, the National Science Foundation Collaborative Research Project Award and the NIH Director’s Pioneer Award. Carl received his M.D. from Columbia University Vagelos College of Physicians and Surgeons and his Ph.D. in immunology from Tufts University.